Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial

Abstract Background A high percentage of epithelial ovarian cancers (EOC) express the estrogen receptor (ER), which is an ideal target for endocrine therapy. Letrozole is a proven, potent aromatase inhibitor, extensively tested and used in the treatment of ER positive breast cancer. In addition, it...

Full description

Bibliographic Details
Published in:BMC Cancer
Main Authors: Pamela M. J. McLaughlin, Maximilian Klar, Tibor A. Zwimpfer, Gilles Dutilh, Marcus Vetter, Christian Marth, Andreas du Bois, Carmen Schade-Brittinger, Alexander Reuss, Claudine Bommer, Christian Kurzeder, Viola Heinzelmann-Schwarz
Format: Article
Language:English
Published: BMC 2022-05-01
Subjects:
Aromatase Inhibitor
Letrozole
Generic
Hormone therapy
Ovarian Cancer
Maintenance therapy
Online Access:https://doi.org/10.1186/s12885-022-09555-8

Internet

https://doi.org/10.1186/s12885-022-09555-8

Similar Items